Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals

R. Faria, B. Woods, S. Griffin, S. Palmer, M. Sculpher, S. D. Ryder

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

3 Invited talk
2 Oral presentation
1 Conference participation

6 results
- Title
- Start date(ascending)

'When and where in the treatment pathway is it appropriate to use new direct acting antivirals for chronic hepatitis C
Faria, R. (Speaker)
Jun 2016
Activity: Talk or presentation › Oral presentation
Challenges in the evaluation and reimbursement of high-cost drugs for large patient populations: the controversy around the new drugs for hepatitis C
Faria, R. (Speaker)
May 2016
Activity: Talk or presentation › Oral presentation
Prevention of progression to cirrhosis in hepatitis C with fibrosis:Effectiveness and cost effectiveness of sequential therapy.
Faria, R. (Invited speaker)
15 Mar 2016
Activity: Talk or presentation › Invited talk

File
How can we treat hepatitis C patients in the most cost-effective way?
Faria, R. (Invited speaker) & Brittain, J. (Invited speaker)
26 Jan 2016
Activity: Talk or presentation › Invited talk
HTAi 2016 Annual Meeting
Faria, R. (Participant)
2016 → …
Activity: Participating in or organising an event › Conference participation
Economic analysis to support NHS implementation of hepatitis C drugs
Faria, R. (Invited speaker)
29 Sept 2015
Activity: Talk or presentation › Invited talk